SC: Public Premises Act Prevails over State Rent Laws For Evicting Unauthorised Occupants || SC: Doctors Were Unwavering Heroes in COVID-19, and Their Sacrifice Remains Indelible || SC Sets Up Secondary Medical Board to Assess Passive Euthanasia Plea of Man in Vegetative State || NCLAT: Amounts Listed As ‘Other Advances’ in Company’s Balance Sheet aren’t Financial Debt under IBC || NCLT Ahmedabad: Objections to Coc Cannot Bar RP From Challenging Preferential Transactions || J&K&L HC: Courts Should Exercise Caution When Granting Interim Relief in Public Infrastructure Cases || Bombay HC: SARFAESI Sale Invalid if Sale Certificate is Not Issued Prior to IBC Moratorium || Supreme Court: Police May Freeze Bank Accounts under S.102 CrPC in Prevention of Corruption Cases || SC: Arbitrator’s Mandate Ends on Time Expiry; Substituted Arbitrator Must Continue After Extension || SC: Woman May Move Her Department’s ICC For Harassment by Employee of Another Workplace

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :